NASDAQ Global Market • Healthcare • Biotechnology • US • USD
Aeglea BioTherapeutics, Inc. (AGLE) has a consensus analyst rating of Hold, based on 8 analysts covering the stock. Of those, 3 recommend buying, 5 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
